Monte Rosa (GLUE) CEO Warmuth sells 5,466 shares under 10b5-1 plan

Rhea-AI Filing Summary

Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 5,466 shares of common stock at a weighted average price of $17.9243 per share on March 2, 2026. The trades occurred between $17.50 and $18.46 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. After these transactions, he directly holds 613,471 shares of Monte Rosa Therapeutics common stock.

Insider Trade Summary

Net Seller: 5,466 shares ($97,974)

Net Sell 1 txn

Insider Warmuth Markus

Role President & CEO

Sold 5,466 shs ($98K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,466	$17.9243	$98K

Holdings After Transaction: Common Stock — 613,471 shares (Direct)

Footnotes (1)

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warmuth Markus

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MA 02118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		5,466	D	$17.9243(2)	613,471	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Markus Warmuth	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Monte Rosa Therapeutics (GLUE) report for Markus Warmuth?

Monte Rosa Therapeutics reported that President & CEO Markus Warmuth sold 5,466 shares of common stock. The open-market transactions occurred on March 2, 2026 at a weighted average price of $17.9243 per share under a Rule 10b5-1 trading plan.

At what prices did Markus Warmuth sell GLUE shares in this Form 4?

The reported weighted average sale price was $17.9243 per share. Individual trades were executed in multiple transactions at prices ranging from $17.50 to $18.46, according to the disclosure that these sales were aggregated as a weighted average.

How many Monte Rosa Therapeutics shares does Markus Warmuth still own after this sale?

After the reported transactions, Markus Warmuth directly owns 613,471 shares of Monte Rosa Therapeutics common stock. This figure reflects his direct holdings following the sale of 5,466 shares disclosed in the Form 4 insider trading report.

Was Markus Warmuth’s March 2026 GLUE share sale under a trading plan?

Yes. The filing states the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. Such plans allow pre-arranged trades, helping insiders diversify holdings while limiting concerns about trading on nonpublic information.

What type of insider transaction code was used in the GLUE Form 4 filing?

The transactions are coded “S”, indicating a sale in the open market or a private transaction. The Form 4 further describes these as open-market sales of common stock, with pricing disclosed as a weighted average and a detailed price range.